Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone

Shaila D Ghanekar1 University of South Florida (USF), Department of Neurology, Tampa, FL, USA;2 USF Ataxia Research Center, Department of Neurology, Tampa, FL, USA

Wai Wai Miller1 University of South Florida (USF), Department of Neurology, Tampa, FL, USA;2 USF Ataxia Research Center, Department of Neurology, Tampa, FL, USA;3 USF Movement Disorders Neuromodulation Center, Department of Neurology, Tampa, FL, USA

https://orcid.org/0000-0003-2913-6676

Colin J Meyer4 Reata Pharmaceuticals, Inc., Department of Product Development, Irving, TX, USA

Kevin J Fenelon1 University of South Florida (USF), Department of Neurology, Tampa, FL, USA;2 USF Ataxia Research Center, Department of Neurology, Tampa, FL, USA

Alvin Lacdao1 University of South Florida (USF), Department of Neurology, Tampa, FL, USA;2 USF Ataxia Research Center, Department of Neurology, Tampa, FL, USA

Theresa A Zesiewicz1 University of South Florida (USF), Department of Neurology, Tampa, FL, USA;2 USF Ataxia Research Center, Department of Neurology, Tampa, FL, USA;3 USF Movement Disorders Neuromodulation Center, Department of Neurology, Tampa, FL, USA;5 James A. Haley Veterans’ Hospital, Department of Neurology, Tampa, FL, USACorrespondence[email protected]

Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone

Figures & data

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date